Lymphomas Expressing ALK Fusion Protein(s) Other Than NPM-ALK

• Published in: Blood Vol. 94; no. 10; pp. 3509 - 3515
• Main Authors: Falini, Brunangelo, Pulford, Karen, Pucciarini, Alessandra, Carbone, Antonino, De Wolf-Peeters, Chris, Cordell, Jacqueline, Fizzotti, Marco, Santucci, Antonella, Pelicci, Pier-Giuseppe, Pileri, Stefano, Campo, Elias, Ott, German, Delsol, Georges, Mason, David Y.
• Format: Journal Article
• Language: English
• Published: Washington, DC Elsevier Inc 15-11-1999; The Americain Society of Hematology
• Subjects: Adolescent; Anaplastic Lymphoma Kinase; Biological and medical sciences; Hematologic and hematopoietic diseases; Humans; In Situ Hybridization, Fluorescence; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphoma - enzymology; Lymphoma - genetics; Lymphoma - metabolism; Male; Medical sciences; Protein-Tyrosine Kinases - biosynthesis; Protein-Tyrosine Kinases - genetics; Protein-Tyrosine Kinases - metabolism; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic; Human; Immunohistochemistry; Pathology; Prognosis; Enzyme; Kinase; Lymphoproliferative syndrome; Transferases; Ki1 positive large cell anaplastic lymphoma; Malignant hemopathy; Non Hodgkin lymphoma; Fusion protein
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V94.10.3509.422k36_3509_3515

The tumor cells in ALK-positive lymphoma (“ALKoma”) usually express the product of the NPM-ALK chimeric gene, generated by the t(2;5) chromosomal translocation. However, 10% to 20% of ALK-positive lymphomas express ALK fusion protein(s) other than NPM-ALK, and in this report, we describe the immunohistologic and clinicopathologic features of 15 such cases. The absence of theNPM-ALK fusion gene was confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) in 8 cases and by fluorescence in situ hybridization (FISH) analysis in a further 2 cases. In each case, ALK staining was restricted to the cytoplasm and the N-terminus of NPM to the nucleus (contrasting with lymphomas expressing NPM-ALK in which cytoplasmic as well as nuclear labeling is seen). However, in the course of screening 53 ALK-positive lymphomas, 2 biopsies were found that had a “cytoplasm-only” ALK staining pattern but that nevertheless were shown to carry the (2;5) (by NPM staining and RT-PCR). The 15 cases resembled typical NPM-ALK–positive lymphomas in that all were of T or null phenotype, usually occurred in young male patients, and frequently presented with advanced disease associated with systemic symptoms and extranodal involvement. Moreover, their prognosis was excellent and indistinguishable from that of classical t(2;5)-positive tumors, but was clearly different from that of ALK-negative anaplastic large-cell lymphomas. These results suggest that lymphomas carrying variants of the NPM-ALK fusion protein can be detected by immunostaining for ALK and NPM and also that they can be grouped with classical t(2;5)-positive tumors as a single entity (ALK-positive lymphoma or “ALKoma”) that shows a better prognosis than ALK-negative anaplastic large-cell lymphoma.